Congenital adrenal hyperplasia: Difference between revisions

Jump to navigation Jump to search
No edit summary
(Undo revision 1339906 by Mehrian.jafari (talk))
Line 20: Line 20:
! align="center" style="background:#DCDCDC;" rowspan="2" colspan="2" |Disease
! align="center" style="background:#DCDCDC;" rowspan="2" colspan="2" |Disease
! align="center" style="background:#DCDCDC;" colspan="2" |History and symptoms
! align="center" style="background:#DCDCDC;" colspan="2" |History and symptoms
! align="center" style="background:#DCDCDC;" colspan="6" |Laboratory findings
! align="center" style="background:#DCDCDC;" colspan="3" |Laboratory findings
! align="center" style="background:#DCDCDC;" |Defective gene
! align="center" style="background:#DCDCDC;" |Defective gene
|-
|-
!Blood pressure  
!Blood pressure  
!Genitalia
!Genitalia
!Cortisol
!Increased
!Aldosterone
!Decreased
!Androgens
!Estrogens
!Increased hormone precursors
!Potassium levels
!Potassium levels
!
!
Line 43: Line 40:


* Male: normal or scrotal pigmentation and large phallus   
* Male: normal or scrotal pigmentation and large phallus   
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Low
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Low
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |High
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Relatively low
|
|
* [[Deoxycorticosterone]]
* [[Deoxycorticosterone]]
* 11-Deoxy-[[cortisol]]
* 11-Deoxy-[[cortisol]]
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]], mild elevation
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]], mild elevation
|
* [[Cortisol]]
* [[Corticosterone]]
* [[Aldosterone]]
|
|
* High in salt-wasting type
* High in salt-wasting type
Line 57: Line 54:
* CYP21A1 and CYP21A2 gene
* CYP21A1 and CYP21A2 gene
|-
|-
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Non-classic type
|Non-classic type
|
|
* Normal
* Normal
Line 63: Line 60:
* Female: [[virilization]] after [[puberty]]
* Female: [[virilization]] after [[puberty]]
* Male: normal appearance
* Male: normal appearance
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Low
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Low
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |High
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Relatively low
|
|
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
* Exaggerated [[Androstenedione]], [[DHEA]], and [[17-Hydroxyprogesterone|17-hydroxyprogesterone]] response to [[ACTH]]
* Exaggerated [[Androstenedione]], [[DHEA]], and [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
response to [[ACTH]]
|
* [[Cortisol]]
 
* [[Aldosterone]]
|
|
* Normal
* Normal
Line 81: Line 79:
* Female: normal
* Female: normal
* Male: [[ambiguous genitalia]]
* Male: [[ambiguous genitalia]]
|Normal corticosterone
Normal cortisol
|High
|Low
|Low
|
|
* [[Deoxycorticosterone]]
* [[Deoxycorticosterone]]
* [[Corticosterone]]
* [[Progesterone]]
* [[Progesterone]]
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Low
|
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |[[CYP17A1]]
* [[Cortisol]]
* [[Aldosterone]]
|
* Low
|  
* [[CYP17A1]]
|-
|-
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
|
|  
* [[Hypertension]]
* [[Hypertension]]
|
|
Line 99: Line 98:


* Male: normal or scrotal pigmentation and large phallus
* Male: normal or scrotal pigmentation and large phallus
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Low
|  
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |High
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |High
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Relatively low
|
* [[Deoxycorticosterone]]
* [[Deoxycorticosterone]]
* 11-Deoxy-[[cortisol]]
* 11-Deoxy-[[cortisol]]
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]], mild elevation
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]], mild elevation
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Low
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | CYP11B1
* [[Cortisol]]
* [[Corticosterone]]
* [[Aldosterone]]
|
* Low
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |
* CYP11B1
|-
|-
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |[[3 beta-hydroxysteroid dehydrogenase deficiency]]
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |[[3 beta-hydroxysteroid dehydrogenase deficiency]]
Line 115: Line 116:
|
|
* Both male and female: [[ambiguous genitalia]]
* Both male and female: [[ambiguous genitalia]]
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Low
|  
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Low
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Low in male and high in female
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Low
|
* [[Dehydroepiandrosterone]]
* [[Dehydroepiandrosterone]]
* [[17-hydroxypregnenolone]]
* [[17-hydroxypregnenolone]]
* [[Pregnenolone]]
* [[Pregnenolone]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | High
|
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | HSD3B2  
* [[Cortisol]]
* [[Aldosterone]]
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |
* High
| align="center" style="padding: 5px 5px; background: #F5F5F5;" |
* HSD3B2  
|-
|-
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Cytochrome P450-oxidoreductase (POR) deficiency (ORD)  
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Cytochrome P450-oxidoreductase (POR) deficiency (ORD)  
Line 130: Line 132:
|
|
|  
|  
|
|
|
|
|
|
|
Line 138: Line 137:
|-
|-
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Congenital lipoid adrenal hyperplasia
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Congenital lipoid adrenal hyperplasia
| [[Hypotension]]
|
|
|
|
* [[Hypotension]]
|
|
* Female: normal, no puberty in females
|  
* Male: ambiguous genitalia
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Low
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Low
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Low
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Low
|None of precursors increased
|align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Low
|[[Gene mutation|Gene mutations]] on chromosome 8, codes for a protein called steroid acute regulatory protein (StAR)
|-
|-
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Cholesterol side-chain cleavage enzyme deficiency
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |Cholesterol side-chain cleavage enzyme deficiency
Line 155: Line 148:
|
|
|  
|  
|
|
|
|
|
|
|

Revision as of 16:05, 11 August 2017

This page contains general information about Congenital adrenal hyperplasia. For more information on specific types, please visit the pages on 21-hydroxylase deficiency, 17 alpha-hydroxylase deficiency, 11β-hydroxylase deficiency, 3 beta-hydroxysteroid dehydrogenase deficiency, Cytochrome P450-oxidoreductase (POR) deficiency (ORD), congenital lipoid adrenal hyperplasia, cholesterol side-chain cleavage enzyme deficiency .

Congenital adrenal hyperplasia main page

Overview

Classification

21-hydroxylase deficiency
11β-hydroxylase deficiency
17 alpha-hydroxylase deficiency
3 beta-hydroxysteroid dehydrogenase deficiency
Cytochrome P450-oxidoreductase (POR) deficiency (ORD)
Lipoid congenital adrenal hyperplasia

Differential Diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]

Synonyms and keywords: Congenital adrenal hyperplasia, CAH, Adrenal hyperplasia

Overview

Congenital adrenal hyperplasia consists of several disorders result from defective enzymes and proteins involving in steroid and cortisol biosynthesis. Defects in steroid biosynthesis is caused by several genetic mutations. Decreasing cortisol levels leads to releasing the inhibitory feedback on corticotropin (ACTH) production. High ACTH level causes cortisol precursor accumulation and overproduction of other steroids. The most common cause of congenital adrenal hyperplasia is 21-hydroxylase deficiency, which accounts for more than 95% of cases. Other causes are 21-hydroxylase deficiency, 17 alpha-hydroxylase deficiency, 11β-hydroxylase deficiency, 3 beta-hydroxysteroid dehydrogenase deficiency, Cytochrome P450-oxidoreductase (POR) deficiency (ORD), congenital lipoid adrenal hyperplasia, cholesterol side-chain cleavage enzyme deficiency.

Classification

Congenital adrenal hyperplasia is classified into seven types based on the genetic causes that lead to hyperplasia and hormonal imbalance. There are three zones of hormonal synthesis in adrenal cortex that are shown below, and impairment of each pathway may lead to a specific subtype of congenital adrenal hyperplasia.

Disease History and symptoms Laboratory findings Defective gene
Blood pressure Genitalia Increased Decreased Potassium levels
21-hydroxylase deficiency Classic type
  • Low in salt-wasting
  • Normal in non-salt-wasting
  • Female: ambiguous
  • Male: normal or scrotal pigmentation and large phallus
  • High in salt-wasting type
  • Normal in non-salt wasting
  • CYP21A1 and CYP21A2 gene
Non-classic type
  • Normal

response to ACTH

  • Normal
  • CYP21A1 and CYP21A2 gene
17-α hydroxylase deficiency
  • Low
11-β hydroxylase deficiency
  • Male: normal or scrotal pigmentation and large phallus
  • Low
  • CYP11B1
3 beta-hydroxysteroid dehydrogenase deficiency
  • High
  • HSD3B2
Cytochrome P450-oxidoreductase (POR) deficiency (ORD)
Congenital lipoid adrenal hyperplasia Hypotension
Cholesterol side-chain cleavage enzyme deficiency

Differential Diagnosis

Congenital adrenal hyperplasia must be differentiated from diseases that cause ambiguous genitalia:[1][2]

Disease name Laboratory tests Important clinical findings
Increased Decreased
Classic type of 21-hydroxylase deficiency
11-β hydroxylase deficiency
17-α hydroxylase deficiency
3 beta-hydroxysteroid dehydrogenase deficiency
Gestational hyperandrogenism

Congenital adrenal hyperplasia must be differentiated from diseases that cause virilization and hirsutism in female:[3][2][4]

Disease name Steroid status Other laboratory Important clinical findings
Non-classic type of 21-hydroxylase deficiency Increased:

response to ACTH

  • No symptoms in infancy and male
11-β hydroxylase deficiency Increased:

Decreased:

3 beta-hydroxysteroid dehydrogenase deficiency Increased:

Decreased:

Polycystic ovary syndrome
Adrenal tumors
  • Variable levels depends on tumor type
  • Older age
  • Rapidly progressive symptoms
Ovarian virilizing tumor
  • Variable levels depends on tumor type
  • Older age
  • Rapidly progressive symptoms
Cushing's syndrome
Hyperprolactinemia

Some types of congenital adrenal hyperplasia must be differentiated from diseases with primary amenorrhea and female external genitalia.[5][6][7][8][9][10][11][12]

Disease name Cause Differentiating
Findings Uterus Breast development Testosterone LH FSH Karyotyping
Pregnancy HCG positive
3-beta-hydroxysteroid dehydrogenase type 2 deficiency

Yes in female

Yes in female

Low

Normal

Normal

XY and XX
17-alpha-hydroxylase deficiency

No

No

Low

Normal

Normal

XY

Gonadal dysgenesis
  • Mutations in SRY, FOG2/ZFPM2, and WNT1

Yes

Yes

Low

High

High

XY

Testicular regression syndrome
  • Loss of testicular function and tissue early in development

No

No

Low

High

High

XY

LH receptor defects

No

No

Low

High

High

XY

5-alpha-reductase type 2 deficiency

No

No

Normal male range

High to normal

High to normal

XY

Androgen insensitivity syndrome 

No

Yes

Normal male range

Normal

Normal

XY
Mullerian agenesis

No

Yes

Normal female range

Normal

Normal

XX

Primary ovarian insufficiency

Yes

Yes

Normal female range

High

High

XX

Hypogonadotropic hypogonadism
  • Functional, sellar masses

Yes

No

Normal female range

Low

Normal

XX

Turner syndrome

  • Chromosomal

Yes

Yes

Normal female range

High

High

45 XO

References

  1. Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT (2007). "Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development". Best Pract. Res. Clin. Endocrinol. Metab. 21 (3): 351–65. doi:10.1016/j.beem.2007.06.003. PMID 17875484.
  2. 2.0 2.1 White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.
  3. Hohl A, Ronsoni MF, Oliveira M (2014). "Hirsutism: diagnosis and treatment". Arq Bras Endocrinol Metabol. 58 (2): 97–107. PMID 24830586. Vancouver style error: initials (help)
  4. Melmed, Shlomo (2016). Williams textbook of endocrinology. Philadelphia, PA: Elsevier. ISBN 978-0323297387.=
  5. Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, Cartigny M, Pienkowski C, Polak M, Skordis N, Mazen I, Ocal G, Berberoglu M, Reynaud R, Baumann C, Cabrol S, Simon D, Kayemba-Kay's K, De Kerdanet M, Kurtz F, Leheup B, Heinrichs C, Tenoutasse S, Van Vliet G, Grüters A, Eunice M, Ammini AC, Hafez M, Hochberg Z, Einaudi S, Al Mawlawi H, Nuñez CJ, Servant N, Lumbroso S, Paris F, Sultan C (2011). "Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients". J. Clin. Endocrinol. Metab. 96 (2): 296–307. doi:10.1210/jc.2010-1024. PMID 21147889.
  6. Moreira AC, Leal AM, Castro M (1990). "Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency". J. Clin. Endocrinol. Metab. 71 (1): 86–91. doi:10.1210/jcem-71-1-86. PMID 2164530.
  7. Heremans GF, Moolenaar AJ, van Gelderen HH (1976). "Female phenotype in a male child due to 17-alpha-hydroxylase deficiency". Arch. Dis. Child. 51 (9): 721–3. PMC 1546244. PMID 999330.
  8. Biglieri EG (1979). "Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome". J. Steroid Biochem. 11 (1B): 653–7. PMID 226795.
  9. Saenger P (1996). "Turner's syndrome". N. Engl. J. Med. 335 (23): 1749–54. doi:10.1056/NEJM199612053352307. PMID 8929268.
  10. Bastian C, Muller JB, Lortat-Jacob S, Nihoul-Fékété C, Bignon-Topalovic J, McElreavey K, Bashamboo A, Brauner R (2015). "Genetic mutations and somatic anomalies in association with 46,XY gonadal dysgenesis". Fertil. Steril. 103 (5): 1297–304. doi:10.1016/j.fertnstert.2015.01.043. PMID 25813279.
  11. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (1974). "Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism". Science. 186 (4170): 1213–5. PMID 4432067.
  12. Schnitzer JJ, Donahoe PK (2001). "Surgical treatment of congenital adrenal hyperplasia". Endocrinol. Metab. Clin. North Am. 30 (1): 137–54. PMID 11344932.